GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
MNK is $6 now, $1.75 to $6.10 got to love these lottos.
I had it in the cache mentioned on GBA at $3, got lost. $6.69 now
I had it in the cache mentioned on GBA at $3, got lost. $6.69 now
Your buddy has a nice target on it.
Mizuho has decided to maintain its Buy rating of Coterra Energy(NYSE:CTRA) and raise its price target from $38.00 to $39.00.
Shares of Coterra Energy are trading up 0.86% over the last 24 hours, at $25.67 per share.
A move to $39.00 would account for a 51.93% increase from the current share price.
About Coterra Energy
Coterra is an independent exploration and production company with operations in Appalachia, the Permian Basin, and Oklahoma. It was formed after the 2021 merger with Cabot and Cimarex. At year-end 2022, Coterra's proved reserves were 2.4 billion barrels of oil equivalent, with net production that year of approximately 633 million barrels of oil equivalent per day (of which 74% was natural gas).
First-Quarter 2023 Shareholder Return Highlights
Jorden noted, “Based on first quarter results, Coterra will return $420 million to shareholders, which equals 76% of the company’s Free Cash Flow. The return will include $152 million from our recently increased base dividend ($0.20 per quarter, $0.80 annum) and $268 million via share buybacks. We reiterate our commitment to return 50%+ of Free Cash Flow to shareholders, with an emphasis on the base dividend and buybacks, in the near-term.”
Apparently my data was wrong.
Good catch.
3%
EDIT... OK .. it wasn't my data lol... I looked again at where I had got that number earlier... it was my eyes
3's look like 8's without readers sometimes. Oops.
Last edited:
Anticipation Builds For Rain Oncology's Phase 3 MANTRA Trial Results, Analyst Sees Promise$8-$9 <---------------------------------/// IS MY COST ON RAIN!!!!!!
I JUST TALKED TO BIG PETE WHO'S WALKING INTO A COSTCO...
(THESE BROKERS....)
HE SAYS XIB DOWN RAIN UP -!
RAIN 9.93
QUOTES AS OF 04:00:00 PM ET 05/19/2023
- In early March, in its Q4 earnings release, Rain Oncology Inc (NASDAQ:RAIN) announced that the topline data from its Phase 3 (MANTRA) trial of milademetan (MDM2 inhibitor) vs. Yondelis (trabectedin) in liposarcoma would be delayed by a quarter, with a primary endpoint (progression-free survival, or PFS) readout now slated to occur imminently this quarter.
- Earlier data readout was expected in Q1 of 2023.
- HC Wainwright says this is favorable, as the delay in reaching the required number (105) of PFS events could indicate that the active arm performed well. The analyst reiterates the Buy rating with a price target of $19.
- The analyst estimates about three months of PFS for the control arm.
- The MANTRA trial finished enrolling 175 patients in July 2022, and in its Q1 earnings release, it announced that the required number of PFS events has been reached. PFS data release in 2Q23 suggests at least eight months between the last patient enrolled and the readout.
- The analyst notes that milademetan previously achieved a 7.4- month PFS duration in a Phase 1 trial in liposarcoma patients, more than double the PFS rate for standard-of-care therapies, providing another reason to expect positive results.
- Assuming positive data from the MANTRA trial, the competition might need to improve upon the benchmark set by Rain Oncology, writes the analyst.
- Rain had $109.8 million in cash, cash equivalents, and short-term investments in Q1. But the company did not provide guidance on the cash runway. It is assessing its cash runway and might provide some update after the MANTRA topline results.
Stoney you said you loved BJs in April or March, what happened?
ETF DIVY?8% divy
Buy for Stoney Jr's account and sign up for DRIP
Safe returns are nice.
https://www.soundetfs.com/divy/
Check out the call action on BJ's today.
Bullish as all get out.
Stoney's hypothesis as "a safe stock" back then, applies now more than ever.
Plus they had a great report last Q.
The stock didn't really drop, but it didn't go up either.
$69 today was a solid buy imo.
It's not going away and it's a well run growing company in all the hot markets.
Stoney’s going to pick apart our post and say “You said BJs, huh huh” not to mention it’s price!